Tumor necrosis factor-α: Is there a continuum of liability between stress, anxiety states and anorexia nervosa?

Medical Hypotheses

Volumn 52, Issue 2, 1999, Pages 155-162

  Holden, R J ^a   Pakula, I S ^b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b South Eastern Sydney and Illawarra Area Health Service   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ENDORPHIN; CHOLECYSTOKININ; CYTOKINE; GAMMA INTERFERON; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 4; NEUROPEPTIDE; NEUROPEPTIDE Y; SOMATOSTATIN; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADENOHYPOPHYSIS; ANOREXIA NERVOSA; ANXIETY; BRAIN BLOOD FLOW; BRAIN METABOLISM; ENERGY METABOLISM; GLUCOSE METABOLISM; INSULIN RELEASE; LIMBIC SYSTEM; MENTAL DISEASE; MENTAL STRESS; PRIORITY JOURNAL; REVIEW; SOMATOSTATIN RELEASE; STRESS;

EID: 0033080863     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1997.0641     Document Type: Article

References (83)

1. Mehta V. K., Hao W., Brooks-Worrell B. M., Palmer J. P. Low-dose interleukin 1 and tumor necrosis factor individually stimulate insulin release but in combination cause suppression. Eur J Endocrinol 1994; 130: 208-214.
2. Jhala U., Baly D. L. Effect of chronic IL-1 beta infusion on glucose homeostasis and pancreatic insulin secretion. Life Sciences 1994; 54: 413-422.
3. Arias-Díaz J., Vara E., Gómez M., García C., Moreno A., Balibrea J. L. Effect of cytokines on 'de novo' lipid synthesis and hormone secretion by isolated human islets. Transplantation Proc 1992; 24: 2909-2912.
4. Vara E., Arias-Díaz J., García C., Balibrea J. L. Cytokine-induced inhibition of lipid synthesis and hormone secretion by isolated human islets. Pancreas 1994; 9: 316-323.
5. Eizirik D. L., Sandler S., Welsh N. et al. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J Clin Invest 1994; 93: 1968-1974.
6. Holden R. J., Pakula I. S., Mooney P. A. The role of brain insulin in the neurophysiology of serious mental disorders [review]. Med Hypotheses 1999; 52: in press.
7. Henneberg N., Hoyer S. Short-term or long-term intracerebroventricular (i.c.v.) infusion of insulin exhibits a discrete anabolic effect on cerebral energy metabolism in the rat. Neurosci Lett 1994; 175: 153-156.
8. Clarke D. W., Mudd L. H., Boyd F. T., Fields M., Raizada M. K. Insulin is released from rat brain neuronal cells in culture. J Neurochem 1986; 47: 831-836.
9. Davis S. N., Colburn C., Dobbins R. et al. Evidence that the brain of the conscious dog is insulin sensitive. J Clin Invest 1995; 95: 593-602.
10. Brant A. M., Jess T. J., Milligan G., Brown C. M., Gould G. W. Immunological analysis of glucose transporters expressed in different regions of the rat brain and central nervous system. Biochem Biophys Res Commun 1993; 192: 1297-1302.
11. Rayner D. V., Thomas M. E. A., Trayhurn P. Glucose transporters (GLUTs 1-4) and their mRNAs in regions of the rat brain: Insulin-sensitive transporter expression in the cerebellum. Can J Physiol Pharmacol 1994; 72: 476-479.
12. Livingstone C., Lyall H., Gould G. W. Hypothalamic GLUT 4 expression: A glucose- and insulin-sensing mechanism? Mol Cell Endocrinol 1995; 107: 67-70.
13. Sonnenfeld G., Cunnick J. E., Armfield A. V., Wood P. G., Rabin B. S. Stress-induced alterations in interferon production and class II histocompatibility antigen expression. Brain Behav Immun 1992; 6: 170-178.
14. Zhu G. F., Chancellor-Freeland C., Berman A. S. et al. Endogenous substance P mediates cold water stress-induced increase in interleukin-6 secretion from peritoneal macrophages. J Neurosci 1996; 16: 3745-3752.
15. Yamasu K., Shimada Y., Sakaizumi M., Soma G., Mizuno D. Activation of the systemic production of tumor necrosis factor after exposure to acute stress. Eur Cytokine Netw 1992; 3: 391-398.
16. Arck P. C., Merali F. S., Manuel J., Chaouat G., Clark D. A. Stress-triggered abortion: Inhibition of protective suppression and promotion of tumor necrosis factor-alpha (TNF-alpha) release as a mechanism triggering resorptions in mice. Am J Reprod Immunol 1995; 33: 74-80.
17. Dobbin J. P., Harth M., McCain G. A., Martin R. A., Cousin K. Cytokine production and lymphocyte transformation during stress. Brain Behav Immun 1991; 5: 339-348.
18. Brambilla F., Bellodi L., Perna G., Bertani A., Panerai A., Sacerdote P. Plasma interleukin-1 beta concentrations in panic disorder. Psychiatry Res 1994; 54: 135-142.
19. Abraham E. Effects of stress on cytokine production. Methods Achiev Exp Pathol 1991; 14: 45-62.
20. Schedlowski M., Fluge T., Richter S., Tewes U., Schmidt R. E., Wagner T. O. beta-endorphin, but not substance-P, is increased by acute stress in humans. Psychoneuroendocrinology 1995; 20: 103-110.
21. Gerra G., Volpi R., Delsignore R. et al. ACTH and beta-endorphin responses to physical exercise in adolescent women tested for anxiety and frustration. Psychiatry Res 1992; 41: 179-186.
22. Darko D. F., Risch S. C., Gillin J. C., Golshan S. Association of beta-endorphin with specific clinical symptoms of depression. Am J Psychiatry 1992; 149: 1162-1167.
23. Brady K. T., Lydiard R. B., Ballenger J. C., Shook J., Laria M., Fossey M. CSF opioids in panic disorder. Biol Psychiatry 1991 ; 30: 512-514.
24. Darko D. F., Irwin M. R., Risch S. C., Gillin J. C. Plasma beta-endorphin and natural killer cell activity in major depression: A preliminary study. Psychiatry Res 1992; 43: 111-119.
25. Carr D. J. The role of endogenous opioids and their receptors in the immune system. Proc Soc Exp Biol Med 1991; 198: 710-720.
26. Ohgo S., Nakatsuru K., Ishikawa E., Matsukura S. Stimulation of cholecystokinin (CCK) release from superfused rat hypothalamo-neurophypophyseal complexes by interleukin-1 (IL-1). Brain Res 1992; 593: 25-31.
27. Millington W. R., Mueller G. P., Lavigne G. J. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary. J Pharmacol Exp Ther 1992; 261: 454-461.
28. de Belleroche J. Release of cholecyctokinin in the central nervous system. Neuchochem Int 1993; 22: 519-527.
29. Lydiard R. B. Neuropeptides and anxiety: Focus on cholescystokinin. Clin Chem 1994; 40: 315-318.
30. Rasmusse K., Stockton M. E., Czachura J. F., Howbert J. J. Cholecystokinin (CCK) and schizophrenia: The selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity. Eur J Pharmacol 1991; 209: 135-138.
31. Heilig M., McLeod S., Koob G. K., Britton K. T. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept 1992; 41: 61-69.
32. Wettstein J. G., Earley B., Junien J. L. Central nervous system pharmacology of neuropeptide Y. Pharmac Ther 1995; 65: 397-414.
33. Zarjevski N., Cusin I., Vettor R., Rohner-Jeanrenaud F., Jeanrenaud-B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993; 133: 1753-1758.
34. Sipols A. J., Baskin D. G., Schwartz M. W. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 1995; 44: 147-151.
35. Melchior J. C., Rigaud D., Colas-Linhart N., Petiet A., Girard A., Apfelbaum M. Immunoreactive beta-endorphin increases after an aspartame chocolate drink in healthy human subjects. Physiol Behav 1991; 50: 941-944.
36. Lucey J. V., Costa D. C., Blanes T. Regional cerebral blood flow in obsessive-compulsive disordered patients at rest. Differential correlates with obsessive-compulsive and anxious-avoidant dimensions. Br J Psychiatry 1995; 167: 629-634.
37. Hoehn-Saric R., Pearlson G. D., Harris G. J., Machlin S. R., Camargo E. E. Effects of fluoxetine on regional cerebral blood flow in obsessive-compulsive patients. Am J Psychiatry 1991; 148: 1243-1245.
38. Machlin S. R., Harris G.J., Pearlson G. D., Hoehn-Saric R., Jeffery P., Camargo E. E. Elevated medial-frontal cerebral blood flow in obsessive-compulsive patients: A SPECT study. Am J Psychiatry 1991; 148: 1240-1242.
39. McGuire P. K., Bench C. J., Frith C. D., Marks I. M., Frackowiak R. S. Dolan R. J. Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry 1994; 164: 459-468.
40. Woods S. W. Regional cerebral blood flow imaging with SPECT in psychiatric disease: Focus on schizophrenia, anxiety disorders, and substance abuse. J Clin Psychiatry 1992; 53(Suppl): 20-25.
41. Rauch S. L., van der Kolk B. A., Fisler R. E. et al. A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery. Arch Gen Psychiatry 1996; 53: 380-387.
42. Fredrikson M., Wik G., Greitz T. et al. Regional cerebral blood flow during experimental phobic fear. Psychophysiology 1993; 30: 126-130.
43. O'Carroll R. E., Moffoot A. P., Van-Beck M. et al. The effect of anxiety induction on the regional uptake of 99mTc-exametazime in simple phobia as shown by single photon emission tomography (SPET). J Affect Disord 1993; 28: 203-210.
44. Ableitner A., Schulz R. Neuroanatomical sites mediating the central actions of beta-endorphin as mapped by changes in glucose utilization: Involvement of mu opioid receptors. J Pharmacol Exp Ther 1992; 262: 415-423.
45. Keymeulen B., Jacobs A., de Metz K., de Sadeleer C., Bossuyt A., Somers G. Regional cerebral hypoperfusion in long-term type 1 (insulin-dependent) diabetic patients: Relation to hypoglycaemic events. Nucl Med Commun 1995; 16: 10-16.
46. Fahy T. A., Osacar A., Marks I. History of eating disorders in female patients with obsessive-compulsive disorder. Int J Eat Disord 1993; 14: 439-443.
47. Thiel A., Broocks A., Ohlmeier M., Jacoby G. E., Schussler G. Obsessive-compulsive disorder among patients with anorexia nervosa and bulimia nervosa. Am J Psychiatry 1995; 152: 72-75.
48. Schattner A., Tepper R., Steinbock M., Schoenfeld A., Vaisman N., Hahn T. [Cytokines in anorexia nervosa - Nutritional or neuroimmunal changes?]. Harefuah 1992; 123: 245-247, 308.
49. Pomeroy C., Eckert E., Hu S. et al. Role of interleukin-6 and transforming growth factor-beta in anorexia nervosa. Biol Psychiatry 1994; 36: 836-839.
50. Nolten W. E., Goldstein D., Lindstrom M. et al. Effects of cytokines on the pituitary-adrenal axis in cancer patients. J Interferon Res 1993; 13: 349-357.
51. Gross M. J., Kahn J. P., Laxenaire M., Nicolas J. P., Burlet C. [Corticotropin-releasing factor and anorexia nervosa: Reactions of the hypothalamus-pituitary-adrenal axis to neurotropic stress]. Ann Endocrinol Paris 1994; 55: 221-228.
52. Bessler H., Karp L., Notti I. et al. Cytokine production in anorexia nervosa. Clin Neuropharmacol 1993; 16: 237-243.
53. Lapchak P. A., Araujo D. M. Interleukin-2 regulates monoamine and opioid peptide release from the hypothalamus. Neuroreport 1993; 4: 303-306.
54. Spangelo B. L., Gorospe W. C. Role of cytokines in the neuroendocrine-immune system axis. Front Neuroendocrinol 1995; 16: 1-22.
55. Knuth U. A., Friesen H. G. Changes of beta-endorphin and somatostatin concentrations in different hypothalamic areas of female rats after chronic starvation. Life Sci 1983; 827-833.
56. Gambert S. R., Garthwaite T. L., Pontzer C. H., Hagen T. C. Fasting associated with decrease in hypothalamic Β-endorphin. Science 1980; 210: 1271-1272.
57. Ferin M., Van Vugt D., Wardlaw S. The hypothalamic control of the menstrual cycle and the role of the endogenous opioid peptides. Recent Prog Hormone Res 1984; 40: 441-485.
58. Tamai H., Takemura J., Kobayashi N., Matsubayashi S., Matsukura S., Nakagawa T. Changes in plasma cholecystokinin concentrations after oral glucose tolerance test in anorexia nervosa before and after therapy. Metabolism 1993; 42: 581-584.
59. Wlodarczyk-Bisaga K., Bisaga A. [Selected issues of biological aspects of eating disorders]. Psychiatr Pol 1994; 28: 579-591.
60. Kalra S. P., Sahu A., Kalra P. S. Ageing of the neuropeptidergic signals in rats. J Reprod Fertil Suppl 1993; 46: 11-19.
61. Suzuki H., Sugiyama E., Tunru I. S. et al. Suppressive effect of interleukin-4 (IL-4) on IL-6 production by adherent rheumatoid synovial cells. Clin Immunol Immunopathol 1993; 66: 67-72.
62. Chao C. C., Molitor T. W., Hu S. Neuroprotective role of IL-4 against activated microglia. J Immunol 1993; 151: 1473-1481.
63. Eskay R. L., Eiden L. E. Interleukin-1 alpha and tumor necrosis factor-alpha differentially regulate enkephalin, vasoactive intestinal polypeptide, neurotensin, and substance P biosynthesis in chromaffin cells. Endocrinology 1992; 130: 2252-2258.
64. Maimone D., Cioni C., Rosa S., Macchia G., Aloisi F., Annunziata P. Norepinephrine and vasoactive intestinal peptide induce IL-6 secretion by astrocytes: Synergism with IL-1 beta and TNF alpha. J Neuroimmunol 1993; 47: 73-81.
65. Sun L., Ganea D. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex. J Neuroimmunol 1993; 48: 59-69.
66. Ganea D., Sun L. Vasoactive intestinal peptide downregulates the expression of IL-2 but not of IFN gamma from stimulated murine T lymphocytes. J Neuroimmunol 1993; 47: 147-158.
67. Xin Z., Tang H., Ganea D. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production in murine thymocytes activated via the TCR/CD3 complex. J Neurommunol 1994; 54: 59-68.
68. Pope Jr H. G., Hudson J. I. Eating disorders. In: Kaplan H. I., Sadock B. J. (eds) Comprehensive Textbook Of Psychiatry/IV, Vol II, 5th edn. Baltimore: Williams and Wilkins, 1854-1864.
69. Smith B. K., Conn C. A., Kluger M. J. Experimental cachexia: Effects of MCA sarcoma in the fischer rat. Am J Physiol 1993; 265: R376-R384.
70. Berg M., Fraker D. L., Alexander H. R. Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mrna in 3T3-L1 adipocytes. Cytokine 1994; 6: 425-432.
71. Tracey K. J., Cerami A. Tumor necrosis factor and regulation of metabolism in infection: Role of systemic versus tissue levels. PSEBM 1992; 200: 233-239.
72. Czlonkowski A., Stein C., Herz A. Peripheral mechanisms of opioid antinociception in inflammation: Involvement of cytokines. Eur J Pharmacol 1993; 242: 229-235.
73. Moore R., Mills I. H., Forster A. Naloxone in the treatment of anorexia nervosa: Effect on weight gain and lipolysis. J Roy Soc Med 1981; 74: 129-131.
74. Schattner A., Tepper R., Steinbock M., Schoenfeld A., Vaisman N., Hahn T. [Cytokines in anorexia nervosa - Nutritional or neuroimmunologic changes?] Harefuah 1992; 123: 245-247, 308.
75. Schattner A., Tepper R., Steinbock M., Hahn T., Schoenfeld A. TNF, interferon-gamma and cell-mediated cytotoxicity in anorexia nervosa; effect of refeeding. J Clin Lab Immunol 1990; 32: 183-184.
76. Polack E., Nahmod V. E., Emeric-Sauval E. et al. Low lymphocyte interferon-gamma production and variable proliferative response in anorexia nervosa patients. J Clin Immunol 1993; 13: 445-451.
77. Moore M. R., Black P. M. Neuropeptides. Neurosurg Rev 1991; 14: 97-110.
78. Nozaki T., Tamai H., Matsubayashi S., Komaki G., Kobayashi N., Nakagawa T. Insulin response to intravenous glucose in patients with anorexia nervosa showing low insulin response to oral glucose. J Clin Endocrinol Metab 1994; 79: 217-222.
79. Kubota S., Tamai H., Ishimoto-Goto J. et al. Carbohydrate oxidation rates in patients with anorexia nervosa. Metabolism 1993; 42: 928-931.
80. Kobayashi N., Tamai H., Takii M., Matsubayashi S., Nakagawa T. Pancreatic B-cell functioning after intravenous glucagon administration in anorexia nervosa. Acta Psychiatr Scand 1992; 85: 6-10.
81. Nozoe S., Naruo T., Yonekura R. et al. Comparison of regional cerebral blood flow in patients with eating disorders. Brain Res Bull 1995; 36: 251-255.
82. Holden R. J., Pakula I. S. The role tumor necrosis factor-alpha in the pathogenesis of anorexia and bulimia nervosa, cancer cachexia and obesity. Med Hypotheses 1996; 47: 423-438.
83. Jobe L. W., Vertrees S., Wilson C. A. et al. In vivo effects of interleukin-1 beta on blood leukocytes in BB rats prone or resistant to diabetes. Autoimmunity 1992; 11: 233-237.